Cystic fibrosis (CF) is an inherited chronic disease that primarily affects the lungs and digestive system of about 1200 children and adults in the Ireland (70,000 worldwide). A defective gene and its protein product cause the body to produce unusually thick, sticky mucus that clogs the lungs and leads to life-threatening lung infections and obstructs the pancreas and stops natural enzymes from helping the body break down and absorb food.
Our mission is to assist the development of the means to cure and control Cystic Fibrosis (CF), to promote the interests and welfare of persons with Cystic Fibrosis in Ireland and to assume advocacy for them and their needs resultant from their having Cystic Fibrosis (CF).
CFI working with our branches and the generous support from the general public has provided €7.5m to improve CF centres throughout Ireland in 2014 and 2015>
CFI continue to play and important role in ensuring access to new and innovative treatments for CF. Kalydeco (the first drug that treated the underlying cause of CF) was made available in 2013, suitable for around 11% of the CF population in Ireland. CFI are currently seeking additional access to this drug for 2-5 years and access to Orkambi, another new drug treating the underlying cause of CF, which could benefit another 50% of the CF population in Ireland.
CFI are seeking the continued improvement in the rate of double lung transplants. The rate of transplants increased from 4 in 2012 to 19 in 2014 in Ireland. CFI is also supporting the Mater Hospital in terms of the resources required for Post -Transplant care